NCT03182140 (KYSS) is a clinical trial of Kyleena in Contraception, sponsored by Bayer.

Who is sponsoring NCT03182140?

NCT03182140 is sponsored by Bayer.

What drugs are being tested in NCT03182140?

Interventions in NCT03182140: Kyleena.

What condition does NCT03182140 study?

NCT03182140 studies Contraception.

Is NCT03182140 still recruiting?

NCT03182140 is currently completed. Last updated 29 March 2021.

Last reviewed 2021-03-29 · How we verify

NCT03182140: KYSS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

KYleena Satisfaction Study / Observational Study on User Satisfaction With the Levonorgestrel Intrauterine Delivery System Kyleena (LNG-IUS 12) in New Contraceptive Users and After Switching From Another Contraceptive Method

Completed Last updated 29 March 2021

What this trial tests

trial testing Kyleena in Contraception in 1,134 participants. Completed in 31 March 2020.

Timeline

6 July 2017

Primary endpoint
19 December 2019

31 March 2020

Quick facts

Lead sponsor	Bayer
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,134
Start date	6 July 2017
Primary completion	19 December 2019
Estimated completion	31 March 2020
Sites	19 locations across Belgium, Sweden, Germany, Mexico, Norway, Canada, United States, Spain

Drugs / interventions tested

Kyleena — full drug profile →

Conditions studied

Contraception — all drugs for Contraception →

Sponsor

Bayer — full company profile →

Who can join

Eligibility, female only, with Contraception. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main goal of this non-interventional study (NIS) is to evaluate user satisfaction with Kyleena in a real-life setting and to identify factors which influence user satisfaction, taking into account previously used contraceptive methods and reasons for use of Kyleena.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Satisfaction and continuation with LNG-IUS 12: findings from the real-world kyleena® satisfaction study.
Stovall DW, Aqua K, Römer T, Donders G, et al · · 2021 · cited 8× · PMID 34528857 · DOI 10.1080/13625187.2021.1975268
Bleeding profile satisfaction and pain and ease of placement with levonorgestrel 19.5 mg IUD: findings from the Kyleena® Satisfaction study.
Donders G, Kopp Kallner H, Hauck B, Bauerfeind A, et al · · 2023 · cited 6× · PMID 36342694 · DOI 10.1080/13625187.2022.2136939
Insertion experience of women and health care professionals in the Kyleena® Satisfaction Study.
Beckert V, Aqua K, Bechtel C, Cornago S, et al · · 2020 · cited 5× · PMID 32223466 · DOI 10.1080/13625187.2020.1736547
The use of LNG-IUS-19.5 mg in daily gynecological routine practice in Germany: data from the Kyleena™ Satisfaction Study (KYSS).
Römer T, Frenz AK, Dietrich-Ott S, Fiedler A. · · 2024 · PMID 38421421 · DOI 10.1007/s00404-024-07421-5
The use of LNG-IUS-19.5mg in daily gynecological routine practice in Germany: data from the KyleenaTM Satisfaction Study (KYSS)
Römer T, Frenz A, Dietrich-Ott S, Fiedler A. · · 2024 · DOI 10.21203/rs.3.rs-3871431/v1

Verify or expand the search:

Other recruiting trials for Contraception

Currently open trials in the same condition.

NCT07365904 — Investigating Ovulation Inhibition for Use as a Contraceptive · Phase 2 · recruiting
NCT07437495 — Women's Knowledge of Contraception During the Postpartum Period · active not recruiting
NCT06823037 — Hormonal Contraception Access Through Pharmacist Prescribing Implementation · NA · recruiting
NCT07326007 — Verbal Analgesia Versus Standard Technique for Pain Control During Copper T380A Intrauterine Device Insertion in Women W · NA · recruiting
NCT05910580 — Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years · NA · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03182140 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 29 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03182140.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing